Encapsulated cell therapy - Alzheimers's disease - NsGene

Drug Profile

Encapsulated cell therapy - Alzheimers's disease - NsGene

Alternative Names: ECB-AD; ECT-AD; ECT-NGF; NsG0202

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator NsGene
  • Class Cell therapies; Gene therapies; Nerve growth factors
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 11 May 2016 Phase I development is ongoing in Sweden
  • 19 Nov 2008 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 10 Apr 2008 NsGene is seeking licensing or partnering opportunities for NsG 0202 (http://www.nsgene.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top